The UK and US have hammered out a key trade agreement that will preserve no tariffs on British pharmaceutical exports being sold in the US market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to raise funding on drugs through the NHS. This pledge secures that import taxes on these key goods will stay at nothing for a duration of the next three years.
This development comes after earlier statements to significantly raise tariffs on patented pharmaceutical imports, with increases mentioned up to 100%.
"This deal with the United Kingdom reinforces the worldwide climate for new treatments and introduces much-needed balance to American-British pharmaceutical trade," a release said.
Commercial Importance
Drugs are one of the UK's biggest export categories to the US, which is easily the primary destination for major British pharmaceutical firms.
Export figures show that in the 12 months to the end of September, the UK shipped pharmaceutical products totaling billions to the US. This value made up 17.4% of all goods exports in that timeframe.
"This guarantee secures work, boosts capital expenditure and facilitates the UK to establish itself as a worldwide center for life sciences," the Business and Trade Secretary commented.
Key British Pledges
The pact involves several notable changes from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it considers new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a goal to raise total NHS spending on treatments from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Payback Limit: The percentage drug companies must refund to the NHS to control costs will be capped at fifteen percent. Last year, rebates were more than twenty percent.
Broader Context
This agreement comes amid a protracted dispute between the sector and the British authorities over medicine costs and NHS adoption.
This friction were intensified by claims that American patients were charged significantly more for the same drugs than consumers in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been halted or scrapped, while major expansions have been announced toward American operations.
The Science Minister acknowledged that the NHS must increase expenditure on treatments, noting that its budget allocation on drugs had declined as a share of its overall budget over the previous ten-year period.
